Managing Pediatric Fever

Managing Pediatric Fever

Guides age-stratified evaluation of the febrile child using validated risk-stratification protocols (Rochester criteria, Philadelphia protocol, Step-by-Step approach, AAP 2021 febrile infant guideline), empiric management algorithms, and disposition decision-making. Covers neonates through older children with emphasis on the critical 0-60 day age group.

Why This Skill Exists

Fever is the most common reason for pediatric emergency department visits. While most febrile children have benign viral illnesses, the risk of serious bacterial infection (SBI) — including UTI, bacteremia, and meningitis — varies dramatically by age. A 10-day-old with 38.1°C requires a full sepsis workup and empiric antibiotics; a well-appearing 3-year-old with 39.5°C and clear URI symptoms may need nothing more than reassurance. The AAP 2021 Clinical Practice Guideline for febrile infants 8-60 days standardized what had been highly variable practice. This skill enforces age-appropriate workup intensity and disposition decisions.

Checkpoint A — Intake Verification

Required Intake Questions

1. What is the child's exact age in days/weeks/months?
2. What is the temperature, method of measurement, and time of measurement?
3. Was the child born at term (≥ 37 weeks)? Any NICU stay or perinatal complications?
4. Has the child received any antibiotics in the last 48-72 hours?
5. What is the child's immunization status (particularly for ages 2-6 months)?
6. What are the associated symptoms (cough, rhinorrhea, vomiting, diarrhea, rash, irritability, lethargy)?
7. How is the child feeding and behaving (alert, interactive, consolable)?
8. Are there any chronic medical conditions or immunodeficiency?

Required Documents

• Vital signs including temperature (rectal is gold standard for infants < 3 months)
• Physical examination with documentation of clinical appearance
• Prior fever workup results (if this is a follow-up)
• Immunization record

For infants < 3 months: ONLY rectal temperature is accepted. Axillary, tympanic, and temporal readings are unreliable in this age group. Rectal temperature ≥ 38.0°C (100.4°F) defines fever.

Step 1 — Age Stratification and Initial Approach

Age 0-28 Days (Neonate) — HIGH RISK

All febrile neonates require full evaluation and empiric antibiotics regardless of appearance.

Mandatory Workup

• CBC with differential
• Blood culture
• Urinalysis and urine culture (catheterized specimen)
• Lumbar puncture: CSF cell count, glucose, protein, Gram stain, culture
• CSF HSV PCR (if < 21 days, or if clinical concern for HSV at any neonatal age)
• Consider: CRP, procalcitonin, CSF enterovirus PCR (if season-appropriate)
• Chest X-ray if respiratory symptoms present

Empiric Treatment

• Ampicillin 75 mg/kg/dose IV Q8h (covers Listeria, GBS, enterococcus)
• Gentamicin 4-5 mg/kg/dose IV Q24h OR cefotaxime 50 mg/kg/dose IV Q8h (covers gram-negatives)
• ADD acyclovir 20 mg/kg/dose IV Q8h if: age < 21 days, vesicular lesions, seizures, CSF pleocytosis, elevated LFTs, maternal history of HSV, or ill appearance

Disposition

• Admit ALL febrile neonates ≤ 28 days to hospital pending culture results (minimum 36-48 hours)

Age 29-60 Days — AAP 2021 Clinical Practice Guideline

Risk Assessment Tools

The AAP 2021 guideline uses a stepwise approach based on inflammatory markers:

Step 1: Assess clinical appearance

• Ill-appearing → full workup + empiric antibiotics + admission (same as neonatal protocol)
• Well-appearing → proceed to laboratory risk stratification

Step 2: Laboratory evaluation (well-appearing 29-60 day infant)

• Urinalysis + urine culture (catheterized) — obtain on ALL
• Inflammatory markers: procalcitonin (PCT), CRP, ANC
  • PCT ≥ 0.5 ng/mL → higher SBI risk
  • ANC ≥ 4000/µL → higher SBI risk
  • CRP ≥ 20 mg/L → higher SBI risk

Step 3: Risk classification

AAP 2021 is specific to well-appearing, term, previously healthy infants 8-60 days. It does NOT apply to: preterm, immunocompromised, prior antibiotics, or ill-appearing infants.

Age 2-3 Months (61-90 Days) — Transitional

• Lower risk of meningitis than younger infants but still requires systematic evaluation
• UA and urine culture for all febrile infants in this age group
• Blood culture and CBC recommended
• LP: perform if ill-appearing, elevated inflammatory markers, or no clear viral source
• If well-appearing with clear viral source (e.g., bronchiolitis with positive RSV): may observe without LP or antibiotics with close follow-up

Age 3-36 Months — Post-PCV13/Hib Era

Risk of Occult Bacteremia

• In the post-conjugate vaccine era, risk of occult bacteremia in fully immunized, well-appearing children with fever is < 0.5%
• Focus shifts to identifying UTI (most common SBI in this age group) and focal bacterial infections

Workup Considerations

• UTI screening: catheterized UA + culture for: all females < 24 months with fever ≥ 39°C and no source; uncircumcised males < 12 months; circumcised males < 6 months
• Blood culture: not routinely needed for well-appearing, fully immunized children with focal viral illness
• Chest X-ray: if fever > 39°C + WBC > 20,000 with no source, or respiratory symptoms with high fever, or fever > 5 days
• High fever without source (≥ 39°C): CBC, blood culture, UA/UCx; consider CRP/PCT

Age > 36 Months — Older Children

• Focus on identifying the source clinically
• Workup guided by clinical findings rather than age-based protocols
• Fever > 5 days without source: evaluate for Kawasaki disease (IVIG criteria)
• Prolonged fever (> 10-14 days): consider FUO workup (CBC, CRP/ESR, blood cultures, ANA, LDH, uric acid, peripheral smear)

Step 2 — Fever Management (Symptomatic Treatment)

Antipyretics

Important Counseling Points

• Fever itself is not dangerous up to 40-41°C in immunocompetent children — it is a normal immune response
• Goal of antipyretics is comfort, NOT normalization of temperature
• Alternating acetaminophen and ibuprofen: AAP does not formally recommend this but acknowledges its common use; if done, careful dosing schedules to avoid confusion
• Do NOT use aspirin in children (Reye syndrome risk)
• Tepid sponge baths are not recommended (cause shivering, which raises core temperature)

Step 3 — Disposition and Follow-Up

Admission Criteria

• All febrile neonates ≤ 28 days
• Ill-appearing infants or children at any age
• Infants 29-60 days with positive UA or elevated inflammatory markers pending cultures
• Clinical suspicion for meningitis, bacteremia, or severe focal infection
• Inability to ensure reliable follow-up within 24 hours

Discharge Criteria (For Low-Risk Infants Sent Home)

• Well-appearing on reassessment
• Adequate oral intake
• Reliable caregiver with transportation
• Clear return precautions provided in writing
• Follow-up within 24 hours confirmed (appointment scheduled, not "call if worse")
• Pending culture results tracked by responsible provider

Return Precautions (Document These Were Given)

• Return immediately if: lethargy, inconsolable crying, poor feeding, bulging fontanelle, rash (petechial/purpuric), difficulty breathing, fever persists > 48-72 hours, or new symptoms develop

Checkpoint B — Fever Management Review

• Rectal temperature documented (for infants < 3 months)
• Age accurately determined and correct protocol applied
• Clinical appearance assessed and documented (well-appearing vs. ill-appearing)
• Appropriate workup obtained per age group (UA, CBC, blood culture, LP as indicated)
• Inflammatory markers (PCT, CRP, ANC) obtained and interpreted for 29-60 day group
• Empiric antibiotics administered when indicated (with correct dosing)
• HSV evaluation and acyclovir considered for neonates
• Disposition appropriate for risk level
• Return precautions provided and documented
• Follow-up within 24 hours arranged for discharged patients
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Follow AAP 2021 Clinical Practice Guideline: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old
• Apply Rochester criteria, Philadelphia protocol, and Step-by-Step approach as historical context; AAP 2021 supersedes for 8-60 day group
• Follow NRP/neonatal guidelines for 0-7 day febrile infants (not covered by AAP 2021 guideline)
• Procalcitonin (PCT) is the most sensitive single inflammatory marker for SBI in young infants; prioritize its availability
• UTI is the most common SBI across all pediatric age groups — always consider
• Post-PCV13 era: occult bacteremia rate < 0.5% in fully immunized children — do not reflexively obtain blood cultures in well-appearing, immunized older infants
• Kawasaki disease: consider in any child with fever ≥ 5 days without clear source
• Rectal temperature is the only acceptable method for febrile infant evaluation under 3 months
• This skill produces clinical documentation; it does not replace clinical judgment